Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | CHKA | P35790 | 6/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16287253 | 0.94 | CHKA (0.69) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL27906959 | 0.84 | KCNJ1 (0.59) | HRH3 | |
| SCHEMBL1165030 | 0.83 | HRH3 (0.65) | HRH3NCF1KDM4EALDH1A1 | |
| SCHEMBL148919 | 0.82 | KCNJ1 (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL14662334 | 0.82 | LMNA (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL1978437 | 0.82 | LMNA (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL19877217 | 0.82 | BTK (0.61) | NPC1RAB9AKDM4EALDH1A1HDAC6 | |
| SCHEMBL21094080 | 0.81 | HRH3 (0.69) | HRH3KDM4EALDH1A1 | |
| SCHEMBL13293909 | 0.81 | HRH3 (0.69) | HRH3KDM4EALDH1A1 | |
| SCHEMBL21225864 | 0.81 | SIGMAR1 (0.41) | LMNAMC4RCHKAHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-117980297-A | Substituted aminopyridine compounds as EGFR inhibitors | 柳韩洋行 | 2024-05-03 | — | — | CN | disclosed |
| US-20230086884-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023027518-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-02 | — | — | WO | disclosed |
| US-9533965-B2 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-03 | — | — | US | disclosed |
| US-9533965-B2 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-03 | — | — | US | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-B1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813495-A1 | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-12-17 | — | — | EP | disclosed |
| CN-103242273-A | 2-arylbenzofuran-7-methanamide compound, preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2013-08-14 | — | — | CN | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| CN-101277962-A | Bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 | NOVARTIS PHARMA AG (CH) | 2008-10-01 | — | — | CN | disclosed |
| EP-1934223-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Novartis Pharma AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | MAP4K2, MAPKAPK2, MAP3K2 | LMNA 2999/4885MC4R 2278/4885CHKA 326/4885 |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | LMNA 4611/4885MC4R 4019/4885CHKA 2057/4885 |
| US-20230086884-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | LMNA 4611/4885MC4R 4019/4885CHKA 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.